ATE439855T1 - Transformierender wachstumsfaktor alpha enthaltende impfstoffzusammensetzung - Google Patents

Transformierender wachstumsfaktor alpha enthaltende impfstoffzusammensetzung

Info

Publication number: ATE439855T1
Authority: AT; Austria
Prior art keywords: growth factor; composition containing; vaccine composition; transforming growth; factor alpha
Prior art date: 2000-12-06

Application number

AT01999383T

Other languages

English (en)

Inventor

Sierra Aillette Mulet

Rodriguez Rolando Perez

Marinello Gisela Maria Gonzalez

Acosta Anabel Alvarez

Medina Tamara Menendez

Nieto Gerardo Enrique Guillen

Ramirez Belinda Sanchez

Original Assignee

Centro Inmunologia Molecular

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-12-06

Filing date

2001-12-06

Publication date

2009-09-15

2001-12-06 Application filed by Centro Inmunologia Molecular filed Critical Centro Inmunologia Molecular

2009-09-15 Application granted granted Critical

2009-09-15 Publication of ATE439855T1 publication Critical patent/ATE439855T1/de

Links

NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 title 1
102000006747 Transforming Growth Factor alpha Human genes 0.000 title 1
101800004564 Transforming growth factor alpha Proteins 0.000 title 1
229960005486 vaccine Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Microbiology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Gynecology & Obstetrics (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Pregnancy & Childbirth (AREA)
Pulmonology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

AT01999383T 2000-12-06 2001-12-06 Transformierender wachstumsfaktor alpha enthaltende impfstoffzusammensetzung ATE439855T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
CU20000286A CU23077A1 (es)	2000-12-06	2000-12-06	Composicion vacunal que contiene factor de crecimiento transformante (tgf-alfa). su uso en la terapia de enfermedades malignas
PCT/CU2001/000011 WO2002045738A2 (es)	2000-12-06	2001-12-06	Composicion vacunal que contiene factor de crecimiento transformante alfa

Publications (1)

Publication Number	Publication Date
ATE439855T1 true ATE439855T1 (de)	2009-09-15

Family

ID=34109588

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT01999383T ATE439855T1 (de)	2000-12-06	2001-12-06	Transformierender wachstumsfaktor alpha enthaltende impfstoffzusammensetzung

Country Status (21)

Country	Link
US (1)	US20030054011A1 (de)
EP (1)	EP1339425B1 (de)
JP (1)	JP2004521091A (de)
KR (1)	KR100834383B1 (de)
CN (2)	CN1482916A (de)
AR (1)	AR031785A1 (de)
AT (1)	ATE439855T1 (de)
AU (2)	AU2152002A (de)
BR (1)	BR0116017A (de)
CA (1)	CA2430621A1 (de)
CU (1)	CU23077A1 (de)
DE (1)	DE60139633D1 (de)
EA (1)	EA006240B1 (de)
ES (1)	ES2332125T3 (de)
MX (1)	MXPA03005031A (de)
MY (1)	MY141122A (de)
NZ (1)	NZ526283A (de)
PE (1)	PE20020696A1 (de)
UY (1)	UY27060A1 (de)
WO (1)	WO2002045738A2 (de)
ZA (1)	ZA200304416B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CU22979A1 (es) *	2000-12-08	2004-09-09	Centro Inmunologia Molecular	Combinación inmunoterapéutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina
CU23204A1 (es) *	2002-12-27	2007-05-18	Ct Ingenieria Genetica Biotech	Combinaciones de factores reguladores del crecimiento y hormonas para el tratamiento de neoplasias
EP1493445A1 (de) *	2003-07-04	2005-01-05	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Inhibierung von Stress-induzierter Liganden-abhängiger EGFR Aktivierung
CU23297A1 (es) *	2004-11-16	2008-07-24	Ct De Inmunologa A Molecular	Formulaciones inmunoterapã0/00uticas para la inducciã"n de autoanticuerpos bloqueadores de la uniã"n de interleucina-2 a su receptor. su uso en el tratamiento del cã ncer
CU23652A1 (es) *	2007-06-29	2011-05-27	Centro Inmunologia Molecular	Composición vacunal homogénea para el tratamiento del cáncer y su método de obtención
KR101323845B1 (ko)	2011-01-21	2013-10-31	광주과학기술원	외막소포체를 유효성분으로 포함하는 항암용 약제학적 조성물
CU20200032A7 (es) *	2020-06-09	2022-01-13	Ct Inmunologia Molecular	Composiciones vacunales basadas en nano-partículas de fosfatos de calcio para el tratamiento del cáncer
CU24734B1 (es) *	2021-03-30	2025-02-07	Ct Inmunologia Molecular	Composicones vacunales depletantes de factores de crecimiento hematopoyéticos para el tratamiento de enfermedades inflamatorias
CN113855792B (zh) *	2021-12-01	2022-03-01	上海惠盾因泰生物科技有限公司	重组hEGF-CRM197肿瘤治疗性疫苗配制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR920703114A (ko) *	1989-07-14	1992-12-17	원본미기재	접합체 백신을 위한 시토킨 및 호르몬 운반체
IL98528A0 (en) *	1990-06-21	1992-07-15	Merck & Co Inc	Pharmaceutical compositions containing hybrid for killing bladder cancer cells
CU22302A1 (es) *	1990-09-07	1995-01-31	Cigb	Secuencia nucleotidica codificante para una proteina de la membrana externa de neisseria meningitidis y uso de dicha proteina en preparados vacunales
CA2261433A1 (en) *	1993-12-09	1995-06-10	Belinda Sanchez Ramirez	Composition comprising autologous epidermal growth factor
GB2333706A (en) *	1998-02-02	1999-08-04	Merck & Co Inc	Method for increasing muscle mass in animals

2000
- 2000-12-06 CU CU20000286A patent/CU23077A1/es unknown
2001
- 2001-11-29 PE PE2001001201A patent/PE20020696A1/es not_active Application Discontinuation
- 2001-12-05 MY MYPI20015557A patent/MY141122A/en unknown
- 2001-12-05 AR ARP010105663A patent/AR031785A1/es unknown
- 2001-12-06 ES ES01999383T patent/ES2332125T3/es not_active Expired - Lifetime
- 2001-12-06 US US10/003,462 patent/US20030054011A1/en not_active Abandoned
- 2001-12-06 EA EA200300638A patent/EA006240B1/ru not_active IP Right Cessation
- 2001-12-06 BR BR0116017-6A patent/BR0116017A/pt not_active IP Right Cessation
- 2001-12-06 AU AU2152002A patent/AU2152002A/xx active Pending
- 2001-12-06 CA CA002430621A patent/CA2430621A1/en not_active Abandoned
- 2001-12-06 UY UY27060A patent/UY27060A1/es unknown
- 2001-12-06 MX MXPA03005031A patent/MXPA03005031A/es not_active Application Discontinuation
- 2001-12-06 AT AT01999383T patent/ATE439855T1/de not_active IP Right Cessation
- 2001-12-06 AU AU2002221520A patent/AU2002221520B2/en not_active Ceased
- 2001-12-06 JP JP2002547521A patent/JP2004521091A/ja active Pending
- 2001-12-06 CN CNA018214347A patent/CN1482916A/zh active Pending
- 2001-12-06 DE DE60139633T patent/DE60139633D1/de not_active Expired - Lifetime
- 2001-12-06 NZ NZ526283A patent/NZ526283A/en not_active IP Right Cessation
- 2001-12-06 CN CNA2008100876617A patent/CN101406692A/zh active Pending
- 2001-12-06 KR KR1020037007631A patent/KR100834383B1/ko not_active Expired - Fee Related
- 2001-12-06 WO PCT/CU2001/000011 patent/WO2002045738A2/es not_active Ceased
- 2001-12-06 EP EP01999383A patent/EP1339425B1/de not_active Expired - Lifetime
2003
- 2003-06-05 ZA ZA200304416A patent/ZA200304416B/en unknown

Also Published As

Publication number	Publication date
AU2152002A (en)	2002-06-18
US20030054011A1 (en)	2003-03-20
DE60139633D1 (de)	2009-10-01
NZ526283A (en)	2004-11-26
EP1339425B1 (de)	2009-08-19
EA200300638A1 (ru)	2003-10-30
AR031785A1 (es)	2003-10-01
EA006240B1 (ru)	2005-10-27
MXPA03005031A (es)	2004-09-10
AU2002221520B2 (en)	2007-10-11
CN101406692A (zh)	2009-04-15
EP1339425A2 (de)	2003-09-03
BR0116017A (pt)	2004-01-13
WO2002045738A3 (es)	2003-02-20
PE20020696A1 (es)	2002-09-19
ES2332125T3 (es)	2010-01-27
CA2430621A1 (en)	2002-06-13
KR20030061424A (ko)	2003-07-18
CU23077A1 (es)	2005-08-17
CN1482916A (zh)	2004-03-17
MY141122A (en)	2010-03-15
ZA200304416B (en)	2004-07-07
KR100834383B1 (ko)	2008-06-09
WO2002045738A2 (es)	2002-06-13
JP2004521091A (ja)	2004-07-15
UY27060A1 (es)	2002-03-22

Legal Events

Date	Code	Title	Description
2010-02-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DK1390066T3 (da)	2012-07-16	Vaccinesammensætning
DE60045324D1 (de)	2011-01-13	Impfstoffzusammensetzung
DK1296715T3 (da)	2012-02-13	Multivalent vaccinesammensætning
NO20031483L (no)	2003-05-28	Vaksine
ATE321569T1 (de)	2006-04-15	Kombinierte impfstoffzusammensetzungen
DE60143252D1 (de)	2010-11-25	Dentalklebstoffzusammensetzung
FR13C0072I1 (fr)	2014-01-31	Nouvelle composition de vaccin
NO20024172D0 (no)	2002-09-02	Vaksine
EP1226807A4 (de)	2005-08-24	Aushärtbare dentalzusammensetzung
GB0103170D0 (en)	2001-03-28	Vaccine composition
NO20004758D0 (no)	2000-09-22	Vaksinesammensetning
GB0103171D0 (en)	2001-03-28	Vaccine composition
GB0020089D0 (en)	2000-10-04	Vaccine Composition
DK1333853T3 (da)	2012-11-05	Vækstfaktorkompleks
ATE439855T1 (de)	2009-09-15	Transformierender wachstumsfaktor alpha enthaltende impfstoffzusammensetzung
DE60017425D1 (de)	2005-02-17	Antitranspirant zusammensetzung enthaltend mikroemulsionen
AU2002221520A1 (en)	2002-08-22	Vaccine composition containing transforming growth factor alpha
GB0006770D0 (en)	2000-05-10	Vaccine composition
DE60133669D1 (de)	2008-05-29	Insulinähnlichen wachstumsfaktors 1
ITMO20000234A0 (it)	2000-10-26	Preparato per uso esterno
GB0108363D0 (en)	2001-05-23	Vaccine composition
GB0100512D0 (en)	2001-02-21	Vaccine composition
GB0101138D0 (en)	2001-02-28	Vaccine composition